EGA adopts disclosure requirements for the generic, biosimilar and value added medicines industry

January 18, 2016 9:29 AM

EGA members unanimously adopted disclosure rules for the generic, biosimilar and value added medicines industry.

This will form an integral part of the EGA’s Code of Conduct that was adopted one year ago, available here.

The new chapter provides a framework to disclose support for patient organisations, healthcare professionals (HCPs) such as meetings and hospitality or educational support, as well as contributions to healthcare organisations (HCOs). EGA members will have one year to implement the disclosure requirements as they will start recording the data in January 2017 to publicly disclose in 2018.

“We are proud that the European generic, biosimilar and value added medicines industry has taken another bold step to build on its existing Code of Conduct. Disclosure enables the industry, healthcare professionals and patient organisations to jointly promote shared values of transparency, integrity, accountability and collaboration”, stated EGA President Jacek Glinka.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!